Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262483 | 0.82 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL11801523 | 0.82 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL28813664 | 0.79 | POLB (0.33) | POLBCYP3A4CYP2C9CYP2C19CA12 | |
| SCHEMBL21828164 | 0.78 | CYP3A4 (0.41) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL194844 | 0.78 | POLB (0.42) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL14561060 | 0.78 | POLB (0.41) | POLBCYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL7617677 | 0.77 | GAA (0.41) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL1903133 | 0.76 | CA2 (0.42) | POLBCYP3A4CYP2C9CYP2C19CA1 | |
| SCHEMBL31475487 | 0.75 | FOLH1 (0.48) | TSHRPGK1PGK2PGD | |
| SCHEMBL25277788 | 0.74 | POLB (0.40) | POLBCYP3A4CYP2C9CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371459-A | Compound and application thereof | 重庆医药工业研究院有限责任公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240140979-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024076873-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076872-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140979-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | ENTPD5, ENTPD1, ENTPD2 | POLB 1666/4885CYP3A4 2817/4885CYP2C9 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.